Nemaura Medical (NASDAQ:NMRD) Research Coverage Started at HC Wainwright
Posted by ABMN Staff on Mar 29th, 2022
Nemaura Medical logoEquities researchers at HC Wainwright began coverage on shares of Nemaura Medical (NASDAQ:NMRD – Get Rating) in a research report issued on Tuesday, The Fly reports. The firm set a “buy” rating and a $12.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 194.12% from the stock’s current price.
NMRD opened at $4.08 on Tuesday. Nemaura Medical has a twelve month low of $3.51 and a twelve month high of $17.40. The stock has a market capitalization of $98.33 million, a P/E ratio of -7.70 and a beta of -0.10. The company has a debt-to-equity ratio of 8.51, a current ratio of 1.55 and a quick ratio of 1.47. The stock has a 50-day simple moving average of $4.07.
Get Nemaura Medical alerts:
Nemaura Medical (NASDAQ:NMRD – Get Rating) last issued its quarterly earnings data on Friday, February 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).
A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Nemaura Medical by 27.9% during the third quarter. Geode Capital Management LLC now owns 108,215 shares of the company’s stock valued at $650,000 after acquiring an additional 23,593 shares during the last quarter. Renaissance Technologies LLC raised its position in Nemaura Medical by 200.1% in the 3rd quarter. Renaissance Technologies LLC now owns 86,500 shares of the company’s stock worth $520,000 after purchasing an additional 57,674 shares during the period. Millennium Management LLC bought a new stake in Nemaura Medical in the second quarter worth $651,000. ARS Investment Partners LLC boosted its position in Nemaura Medical by 47.1% during the fourth quarter. ARS Investment Partners LLC now owns 61,863 shares of the company’s stock valued at $282,000 after buying an additional 19,799 shares during the period. Finally, Morgan Stanley grew its stake in shares of Nemaura Medical by 6,528.9% during the second quarter. Morgan Stanley now owns 50,313 shares of the company’s stock valued at $521,000 after buying an additional 49,554 shares during the last quarter. Institutional investors and hedge funds own 2.52% of the company’s stock.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
